Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...
Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...
Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.
The macro and thematic equity research group founded by investor and trend spotter James van Geelen saw positive returns - up to 75% - on nearly all of their 2025 calls. Their electronic warfare ...
In this video, Halle C. F. Moore, MD, discusses the EMBER-3 study update evaluating imlunestrant for women with hormone receptor-positive, HER2-negative breast cancer, presented at San Antonio Breast ...
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback